Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

Russell Moser, James Annis, Olga Nikolova, Cliff Whatcott, Kay Gurley, Eduardo Mendez, Kim Moran-Jones, Craig Dorrell, Rosalie C. Sears, Calvin Kuo, Haiyong Han, Andrew Biankin, Carla Grandori, Daniel D. Von Hoff, Christopher J. Kemp

Research output: Contribution to journalArticlepeer-review

Abstract

SIGNIFICANCE: This study utilizes functional genetic and pharmacological profiling of KRAS-mutant pancreatic adenocarcinoma to identify therapeutic strategies and finds that TFIIH inhibition synergizes with TRAIL to induce apoptosis in KRAS-driven pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)3375-3393
Number of pages19
JournalCancer Research
Volume82
Issue number18
DOIs
StatePublished - Sep 16 2022

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL'. Together they form a unique fingerprint.

Cite this